Latest news with #Quantum-SiIncorporated


Business Wire
2 days ago
- Business
- Business Wire
Quantum-Si to Participate in the UBS Precision Medicine Frontiers Summit
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the UBS Precision Medicine Frontiers Summit taking place at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA, August 13-14, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be available for one-on-one meetings throughout the day on Thursday, August 14, 2025, and Jeff Hawkins will participate in the New Dimensions in Proteomics and Cellular Research panel on the same day from 8:15 – 8:50 AM Pacific Daylight Time. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X.


Business Wire
21-07-2025
- Business
- Business Wire
Quantum-Si to Participate in the Canaccord Genuity 45 th Annual Growth Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the Canaccord Genuity 45 th Annual Growth Conference taking place at the InterContinental Boston Hotel, August 12-14, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer will be taking one-on-one meetings throughout the day on Tuesday, August 12, 2025 and will participate in a fireside chat on the same day at 4:00 PM Eastern Time. A live and archived webcast of the event will be available in the 'Investors' section of the Quantum-Si website under Events & Presentations. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X.


Business Wire
14-07-2025
- Business
- Business Wire
Quantum-Si to Report Second Quarter 2025 Financial Results on August 5, 2025
BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) ('Quantum-Si,' 'QSI' or the 'Company'), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the second quarter 2025 on Tuesday, August 5, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X.


Business Wire
19-06-2025
- Business
- Business Wire
Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization
BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) ('Quantum-Si,' 'QSI' or the 'Company'), a proteomics technology company redefining protein analysis through single-molecule detection, announces participation in an expert panel during the upcoming GenomeWeb-hosted webinar, "From Raw to Reusable: Considerations for Data Integration and Real-World Standardization in Proteomics." This one-hour webinar will explore critical strategies for improving the accessibility, integration, and standardization of data across proteomics platforms. Attendees will learn how to deposit data into public repositories, apply metadata annotation best practices, normalize cross-study datasets, and contribute to global standardization initiatives. Industry leaders from Quantum-Si, DNAnexus, Olink (a Thermo Fisher Scientific company), and Northwestern University's Proteomics Center of Excellence will share their perspectives and practical insights through presentations, case studies, and panel discussions. Key Topics Include: Best practices for metadata annotation and reproducibility. Strategies for merging and comparing data across proteomics platforms. Guidance on participating in standardization efforts through community initiatives. Advice on enhancing the visibility and reusability of your proteomics datasets in a global database. Featured Speakers: Meredith Carpenter, PhD, Head of Scientific Affairs, Quantum-Si Cindy Lawley, PhD, Sr. Director, Population Health Proteomic Sciences, Olink, Thermo Fisher Scientific Theresa Wohlever, Sr. Bioinformatics Scientist, DNAnexus Michael Hollas, PhD, Director of Bioinformatics, Proteomics Center of Excellence, Northwestern University Hosted by GenomeWeb, this webinar provides a timely forum for researchers, data scientists, and bioinformaticians to align on best practices and influence the future of data standardization in proteomics. WHERE: Virtual event – registration required. HOW: To register, please complete the registration form. A confirmation email will be sent upon registration. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X.
Yahoo
13-06-2025
- Business
- Yahoo
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRANFORD, Conn., June 13, 2025--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 45,529 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The RSUs will vest 25% on June 20, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the employee's continued employment with Quantum-Si on such vesting dates. The RSUs are subject to the terms and conditions of the 2023 Inducement Plan and a RSU agreement covering the grant. About Quantum-Si Incorporated Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at or follow us on LinkedIn or X. View source version on Contacts Investor Contact Jeff KeyesChief Financial Officerir@ Media Contact Katherine Atkinson SVPCommercial Marketingmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data